Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T03:56:42.951Z Has data issue: false hasContentIssue false

The treatment of autism with pipamperone: A case report

Published online by Cambridge University Press:  23 March 2020

B. Petrosino*
Affiliation:
Psichiatria, Medicina clinica e sperimentale, Caltagirone, Italy
M.S. Signorelli
Affiliation:
Psichiatria, Medicina Clinica e sperimentale, Catania, Italy
F. Magnano di San Lio
Affiliation:
Psichiatria, Medicina Clinica e sperimentale, Catania, Italy
C. Petrosino
Affiliation:
Psichiatria, ASP Catania, Caltagirone, Italy
E. Aguglia
Affiliation:
Psichiatria, Medicina Clinica e sperimentale, Catania, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Adults with autism spectrum disorders (ASD) often have behavioral disorders, like aggression, agitation and self-injury. These problems are frequently severe enough to limit educational and developmental progress. Only risperidone and aripiprazole have so far been approved by the FDA for the treatment of behavioral disturbance associated with autism. These drugs are not very effective in the long term, with little benefits to the social functioning and they are associated with side effects. This case report describes the use of pipamperone, in treating behavioral disorders of a patient with autism spectrum disorder and severe mental retardation.

Case presentation

Here is presented the case of a 32-year-old man with autism spectrum disorder, severe mental retardation (caused by undiagnosed phenylketonuria for the first 3 years of life) treated with antipsychotics since childhood. He showed numerous episodes of psychomotor agitation, hetero-direct physical aggression and self-injury, and movement disorders induced by drugs. Treatment with pipamperone reduced drastically crises of psychomotor agitation, and behavioral disorders, without extrapyramidal side effects, and led to an improvement in social functioning. The control of behavioral symptoms associated with adherence to treatment was maintained for 6-month follow up. These clinical observations are supported by ratings using: ABC, CGI-S and CGI-I, VABS, SAS, AIMS.

Conclusion

This case report provides the first potential evidence that pipamperone may be effective in treating behavioral problems associated with autism spectrum disorders. Moreover, the improvement of social functioning and the lack of extrapyramidal side effects make this drug notable for its effectiveness and tolerability.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1042
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.